Screening prior to biological therapy in Crohn's disease: Adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study

Digestive and Liver Disease

Volumn 46, Issue 10, 2014, Pages 881-886

  van der Have, Mike ^a   Belderbos, Tim D G ^a   Fidder, Herma H ^a   Leenders, Max ^a   Dijkstra, Gerard ^b   Peters, Charlotte P ^c   Eshuis, Emma J ^c   Ponsioen, Cyriel Y ^c   Siersema, Peter D ^a   van Oijen, Martijn G H ^a   Oldenburg, Bas ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Anti TNF therapy; Inflammatory bowel disease; Opportunistic infections; Prevention

Indexed keywords

ADALIMUMAB; ANTINEOPLASTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; ISONIAZID; METHOTREXATE; VALGANCICLOVIR; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CHRONIC LIVER DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; GENITAL HERPES; HEPATITIS B; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INCIDENCE; INTERFERON GAMMA RELEASE ASSAY; LARGE CELL LYMPHOMA; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MILIARY TUBERCULOSIS; MIXED INFECTION; MULTICENTER STUDY (TOPIC); OPPORTUNISTIC INFECTION; PATIENT; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCREENING; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULIN TEST; URINARY TRACT INFECTION; VIRUS REACTIVATION; CLINICAL TRIAL; COMPLICATION; EVALUATION STUDY; MULTICENTER STUDY; NETHERLANDS; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS; UTILIZATION; VIRUS DISEASES;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEPATITIS B; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LINEAR MODELS; MALE; NETHERLANDS; OPPORTUNISTIC INFECTIONS; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RETROSPECTIVE STUDIES; TUBERCULIN TEST; TUBERCULOSIS; VIRUS DISEASES;

EID: 84922265391     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.07.006     Document Type: Article

References (34)

1. Akobeng A.K., Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2004, 1:CD003574.
2. Behm B.W., Bickston S.J. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2008, 1:CD006893.
3. Lawson M.M., Thomas A.G., Akobeng A.K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2006, 3:CD005112.
4. Reinisch W., Sandborn W.J., Rutgeerts P., et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflammatory Bowel Diseases 2012, 18:201-211.
5. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Journal of the American Medical Association 2006, 295:2275-2285.
6. Singh J.A., Wells G.A., Christensen R., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, 2:CD008794.
7. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. New England Journal of Medicine 2001, 345:1098-1104.
8. Peyrin-Biroulet L., Deltenre P., de Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clinical Gastroenterology and Hepatology 2008, 6:644-653.
9. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clinical Gastroenterology and Hepatology 2006, 4:621-630.
10. Colombel J.F., Loftus E.V., Tremaine W.J., et al. Gastroenterology 2004, 126:19-31.
11. Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
12. Lawrance I.C., Radford-Smith G.L., Bampton P.A., et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. Journal of Gastroenterology and Hepatology 2010, 25:1732-1738.
13. Lichtenstein G.R., Abreu M.T., Cohen R., et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940-987.
14. Rahier J.F., Ben-Horin S., Chowers Y., et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn's and Colitis 2009, 3:47-91.
15. Kornbluth A., Sachar D.B. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. American Journal of Gastroenterology 2010, 105:501-523.
16. Carmona L., Gómez-Reino J.J., Rodríguez-Valverde V., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis and Rheumatism 2005, 52:1766-1772.
17. Gomez-Reino J.J., Carmona L., Angel D.M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis and Rheumatism 2007, 57:756-761.
18. Van der Have M., Oldenburg B., Fidder H.H., et al. Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease. Digestive Diseases and Sciences 2013, [Epub ahead of print].
19. Gisbert J.P., Chaparro M., Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2011, 33:619-633.
20. Viget N., Vernier-Massouille G., Salmon-Ceron D., et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008, 57:549-558.
21. Vaughn B.P., Doherty G.A., Gautam S., et al. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflammatory Bowel Diseases 2012, 18:1057-1063.
22. Dye C., Scheele S., Dolin P., et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. Journal of the American Medical Association 1999, 282:677-686.
23. Alter M.J. Epidemiology of hepatitis B in Europe and in worldwide. Journal of Hepatology 2003, 39(Suppl. II):S64-S69.
24. Mow W.S., Abreu-Martin M.T., Papadakis K.A., et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clinical Gastroenterology and Hepatology 2004, 2:309-313.
25. Schoepfer A.M., Flogerzi B., Fallegger S., et al. Comparison of interferon-gamma release assay vs. tuberculin skin test for tuberculosis screening in inflammatory bowel disease. American Journal of Gastroenterology 2008, 103:2799-2806.
26. Papay P., Eser A., Winkler S., et al. Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflammatory Bowel Diseases 2011, 17:84-90.
27. Health Council of the Netherlands Vaccination of young children against tuberculosis 2011, Health Council of the Netherlands, The Hague, publication no. 2011/04.
28. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005, 60:800-805.
29. Naganuma M., Kunisaki R., Yoshimura N., et al. Prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. Journal of Gastroenterology 2013, 48:595-600.
30. Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
31. Van Dartel S.A., Fransen J., Kievit W., et al. Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 2013, 52:1052-1057.
32. Doran M.F., Crowson C.S., Pond G.R., et al. Predictors of infection in rheumatoid arthritis. Arthritis and Rheumatism 2002, 46:2294-2300.
33. Ananthakrishnan A.N., McGinley E.L. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. Journal of Crohn's and Colitis 2013, 7:107-112.
34. Cottone M., Kohn A., Daperno M., et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clinical Gastroenterology and Hepatology 2011, 9:30-35.